Assessment of actual benefits of new drugs by the Transparency Committee;Évaluation du service médical rendu des médicaments par la Commission de la Transparence

Journal Francais d'Ophtalmologie

Volumn 31, Issue 1, 2008, Pages 90-93

  Le Jeunne, C ^a  

^a HÔTEL DIEU   (France)

Author keywords

Actual benefit; Drug assessment; Improvement in actual benefit; National Health Insurance; Risk benefit drug assessment; Transparency Committee

Indexed keywords

ARTICLE; CLINICAL TRIAL; DRUG INDUSTRY; DRUG THERAPY; HUMAN; RISK ASSESSMENT; STANDARD; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; DRUG THERAPY; HUMANS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 39749184951     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0181-5512(08)70341-3     Document Type: Article

References (7)

1. Bouvenot G. The French National Medicines Assessment Committee, innovation and therapeutic progress. Therapie, 2006;61:13-6.
2. Code de Sécurité Sociale. Articles R. 163-1 à R 163-21.
3. Bouvenot G. Medical benefits from drugs. Joint Bone Spine, 2006;73:231-3.
4. Le Pen C, Priol G, Lilliu H. What criteria for pharmaceuticals reimbursement? An empirical analysis of the evaluation of “medical service rendered” by reimbursable drugs in France. Eur J Health Econ, 2003;4:30-6.
5. Castaigne A. Role of drugs in therapeutic strategies. Rev Prat, 2002;52:491-6.
6. Massol J, Le Jeunne Cl. Comment évaluer l’intérêt des médicaments. Presse Med, 2007;36:1-7.
7. Le Jeunne Cl. Amélioration du Service Médical Rendu. Rev Prat Med Gen, 2003;17:1087-9.